)
Visual21 Nov 2025
Data center suppliers
Xilio Therapeutics (XLO) investor relations material
Xilio Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Focused on developing tumor-activated immuno-oncology therapies, with lead candidates vilastobart and efarindodekin alfa in clinical trials; vilastobart showed a 40% ORR in high plasma TMB MSS mCRC patients without liver metastases, and efarindodekin alfa demonstrated promising activity and safety.
Achieved a $17.5M milestone from Gilead for initiating a Phase 2 trial of efarindodekin alfa.
Entered a major collaboration with AbbVie, receiving $52M in upfront and equity payments, and eligible for up to $2.1B in milestones.
Closed a $50M follow-on public offering in June 2025, with potential for $100M more if warrants are exercised.
Announced new preclinical data for masked T cell engager programs, supporting best-in-class potential and broad therapeutic index.
Financial highlights
Cash and cash equivalents were $103.8M as of September 30, 2025, up from $55.3M at year-end 2024, driven by $52M from AbbVie and $47M from a June 2025 public offering.
Collaboration and license revenue rose to $30.1M for the nine months ended September 30, 2025, with $19.1M in Q3 2025, mainly from AbbVie and Gilead.
Net loss for the nine months ended September 30, 2025 was $45.4M; Q3 2025 net loss was $16.3M.
Operating expenses increased to $60.2M for the nine months ended September 30, 2025, from $51.6M in the prior year.
R&D expenses rose to $14.3M in Q3 2025 and $37.9M for the nine months ended September 30, 2025.
Outlook and guidance
Cash and equivalents, plus the Gilead milestone, expected to fund operations into Q1 2027.
IND submission for XTX501 planned for mid-2026; masked T cell engager programs to enter IND-enabling studies, with INDs expected in 2027.
Substantial doubt remains about ability to continue as a going concern without additional capital.
Additional funding may come from warrant exercises, milestone payments, equity/debt offerings, or partnerships.
Focused on execution across clinical programs and advancing pipeline candidates.
How will Xilio extend its cash runway past Q1 2027?
Detail equity issuance restrictions from warrant holders.
Impact of BIOSECURE Act on WuXi Biologics reliance?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Xilio Therapeutics earnings date
Q4 202511 Mar, 2026
Next Xilio Therapeutics earnings date
Q4 202511 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm focusing on discovering and developing tumor-activated immuno-oncology therapies. It focuses on creating treatments that are activated in the tumor environment, aiming to enhance the efficacy of immuno-oncology treatments while minimizing side effects. The company's portfolio includes a checkpoint inhibitor program with XTX101, an anti-CTLA-4 monoclonal antibody, alongside cytokine programs featuring XTX202 (a tumor-activated IL-2) and XTX301 (an engineered IL-12 molecule). The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage